Can a statin boost liver cancer survival?
NCT ID NCT01903694
First seen Feb 12, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib could help people with advanced liver cancer live longer. It included 474 adults with Child-Pugh A cirrhosis who could not have curative treatments. The goal was to see if the combination improved overall survival and quality of life compared to sorafenib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILD-PUGH A HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079, France
Conditions
Explore the condition pages connected to this study.